SEARCH

SEARCH BY CITATION

References

  • Anon. (2009) Trial to Assess Efficacy and Safety of Lacosamide in Subjects With Osteoarthritis of the Knee. Study NCT00485472. NIH clinical trial registry (http://www.clinicaltrial.gov).
  • Anon. (2010a) Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome. Study NCT00401830. NIH clinical trial registry (http://www.clinicaltrial.gov).
  • Anon. (2010b) A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis (SP906). Study NCT00440518. NIH clinical trial registry (http://www.clinicaltrial.gov).
  • Aronson JK. (2005) Metameta-analysis. Br J Clin Pharmacol60:117119.
  • Baker GA, Jacoby A, Buck D, Stalgis C, Monnet D. (1997) Quality of life of people with epilepsy: a European study. Epilepsia38:353362.
  • Beghi E, Di Mascio R, Tognoni G. (1986) Adverse effects of anticonvulsant drugs – a critical review. Adverse Drug React Acute Poisoning Rev5:6386.
  • Ben-Menachem E. (2004) Pregabalin pharmacology and its relevance to clinical practice. Epilepsia45(Suppl. 6):1318.
  • Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. (2007) Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia48:13081317.
  • Chadwick DW, Marson AG. (2000) Zonisamide for drug-resistant partial epilepsy. Cochrane Database Syst Rev2:CD001416. Review. Update in: Cochrane Database Syst Rev 2002:CD001416.
  • Chadwick DW, Marson AG. (2002) Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev2:CD001416.
  • Chadwick DW, Marson AG. (2005) Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev4:CD001416.
  • Chaisewikul R, Privitera MD, Hutton JL, Marson AG. (2001) Levetiracetam add-on for drug-resistant localization related (partial) epilepsy. Cochrane Database Syst Rev1:CD001901.
  • Chung SS. (2010) Lacosamide: new adjunctive treatment option for partial-onset seizures. Expert Opin Pharmacother11:15951602.
  • Chung S, Sperling MR, Biton V, Krauss G, Hebert D, Rudd GD, Doty P; SP754 Study Group. (2010) Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia51:958967.
  • Degiorgio CM. (2010) Atrial flutter/atrial fibrillation associated with lacosamide for partial seizures. Epilepsy Behav18:322324.
  • Errington AC, Stöhr T, Heers C, Lees G. (2008) The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol73:157169.
  • Fadda V, Maratea D, Trippoli S, Messori A. (2011) Network meta-analysis. Results can be summarised in a simple figure. BMJ23:342:d1555.
  • Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, Rosenow F, Doty P, Hebert D, Sullivan T; SP755 Study Group. (2009) Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia50:443453.
  • Hemming K, Maguire MJ, Hutton JL, Marson AG. (2008) Vigabatrin for refractory partial epilepsy. Cochrane Database Syst Rev16:(3):CD007302.
  • Henschel AD, Rothenberger LG, Boos J. (2010) Randomized clinical trials in children – ethical and methodological issues. Curr Pharm Des16:24072415.
  • Hillenbrand B, Wisniewski I, Jürges U, Steinhoff BJ. (2011) Add-on lacosamide: a retrospective study on the relationship between serum concentration, dosage, and adverse events. Epilepsy Behav22:548551.
  • Hoppener RJ, Kuyer A, Meijer JWA, Hulsman J. (1980) Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects. Epilepsia21:341350.
  • Jette NJ, Marson AG, Kadir ZA, Hutton JL. (2000) Topiramate for drug-resistant partial epilepsy. Cochrane Database Syst Rev2:CD001417.
  • Jette NJ, Marson AG, Hutton JL. (2002) Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev3:CD001417.
  • Jette N, Hemming K, Hutton JL, Marson AG. (2008) Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev16(3):CD001417.
  • Johannessen Landmark C. (2008) Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs22:2747.
  • Kalume F, Yu FH, Westenbroek RE, Scheuer T, Catterall WA. (2007) Reduced sodium current in Purkinje neurons from Nav1.1 mutant mice: implications for ataxia in severe myoclonic epilepsy in infancy. J Neurosci27:1106511074.
  • Leach JP, Marson AG, Hutton JL. (2002) Remacemide for drug-resistant localization related epilepsy. Cochrane Database Syst Rev4:CD001900.
  • Lièvre M, Cucherat M, Leizorovicz A. (2002) Pooling, meta-analysis, and the evaluation of drug safety. Curr Control Trials Cardiovasc Med3:6.
  • Lozsadi D, Hemming K, Marson AG. (2008) Pregabalin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev23:CD005612.
  • Marson AG, Kadir ZA, Hutton JL, Chadwick DW. (1997) The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia38:859880.
  • Marson AG, Kadir ZA, Hutton JL, Chadwick DW. (2000) Gabapentin for drug-resistant partial epilepsy. Cochrane Database Syst Rev2:CD001415.
  • Marson AG, Hutton JL, Leach JP, Castillo S, Schmidt D, White S, Chaisewikul R, Privitera M, Chadwick DW. (2001) Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res46:259270.
  • Michael B, Marson AG. (2008) Clobazam as an add-on in the management of refractory epilepsy. Cochrane Database Syst Rev16:CD004154.
  • Nizam A, Mylavarapu K, Thomas D, Briskin K, Wu B, Saluja D, Wong S. (2011) Lacosamide-induced second-degree atrioventricular block in a patient with partial epilepsy. Epilepsia52:e153e155.
  • Novy J, Patsalos PN, Sander JW, Sisodiya SM. (2011) Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction?Epilepsy Behav20:2023.
  • Pereira J, Marson AG, Hutton JL. (2002) Tiagabine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev3:CD001908.
  • Perucca P, Carter J, Vahle V, Gilliam FG. (2009) Adverse antiepileptic drug effects. Toward a clinically and neurobiologically relevant taxonomy. Neurology72:12231229.
  • Ramaratnam S, Marson AG, Baker GA. (2000) Lamotrigine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev3:CD001909. Review. Update in: Cochrane Database Syst Rev. 2001:CD001909.
  • Rauck RL, Shaibani A, Biton V, Simpson J, Koch B. (2007) Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clin J Pain23:150158.
  • RevMan (2011) Review Manager (RevMan) [Computer program]. Version 5.1. The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen.
  • Ryvlin P, Perucca E, Rheims S. (2008) Pregabalin for the management of partial epilepsy. Neuropsychiatr Dis Treat4:12111224.
  • Sake JK, Hebert D, Isojärvi J, Doty P, De Backer M, Davies K, Eggert-Formella A, Zackheim J. (2010) A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs24:10551068.
  • Shaibani A, Fares S, Selam JL, Arslanian A, Simpson J, Sen D, Bongardt S. (2009) Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial. J Pain10:818828.
  • Shukralla AA, Tudur-Smith C, Marson AG. (2001) Adverse events of antiepileptic drugs across indications: can randomized controlled trials data from non-epilepsy indications be included in meta-analysis for AEDs used in epilepsy? Special Issue: 29th International Epilepsy Congress, Rome, 28th August–1st September 2011; August 2011 Volume 52, Issue Supplement s6 Pages 1–298.
  • Stephen LJ, Kelly K, Parker P, Brodie MJ. (2011) Adjunctive lacosamide in clinical practice: sodium blockade with a difference?Epilepsy Behav22:499504.
  • Thompson SG, Higgins JP. (2002) How should meta-regression analyses be undertaken and interpreted?Stat Med21:15591573.
  • Wymer JP, Simpson J, Sen D, Bongardt S; Lacosamide SP742 Study Group. (2009) Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin J Pain25:376385.
  • Zaccara G, Cincotta M, Borgheresi A, Balestrieri F. (2004) Adverse motor effects induced by antiepileptic drugs. Epileptic Disord6:153168.
  • Zaccara G, Franciotta D, Perucca E. (2007) Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia48:12231244.
  • Zaccara G, Gangemi P, Perucca P, Specchio L. (2011) The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia52:826836.
  • Zaccara G, Perucca P, Gangemi G. (2012) The adverse event profile of pregabalin across different disorders: a meta-analysis. Eur J Clin Pharmacol68:903912.
  • Ziegler D, Hidvegi T, Gurieva I, Bongardt S, Freynhagen R, Sen D, Sommerville K; on behalf of the Lacosamide SP743 study group. (2010) Efficacy and safety of lacosamide in painful diabetic neuropathy. Diabetes Care33:839841.
  • Zlott DA, Byrne M. (2010) Mechanisms by which pharmacologic agents may contribute to fatigue. PM R2:451455.